← Back to Clinical Trials
Recruiting NCT05589974

Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Central Serous Chorioretinopathy
Sponsor Helse Stavanger HF
Study Type OBSERVATIONAL
Phase N/A
Enrollment 50
Sex ALL
Min Age 18 Years
Max Age 70 Years
Start Date 2022-10-01
Completion 2025-12-31
Interventions
Verteporfin

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Patients with central serous chorioretinopathy (CSC) will be monitored with laser speckle flow graphy (LSFG), swept source optical coherence tomography (SS-OCT) and SS-OCT angiography (SS-OCTA). The aim is to unveil the flow and pulse wave characteristics of the choroidal circulation in acute CSC and chronic CSC.

Eligibility Criteria

Inclusion Criteria:- * Able to sign informed consent * Possible to obtain fundus imaging * Acute CSC ˂4 months of duration in one eye, defined as: 1. Subfoveal presence of SRF on OCT 2. Present attack is 1st -3rd attack of CSC b) Patient history and examination consistent with acute CSC c) Characteristic appearance of acute CSC on fundus autofluorescence (FAF) and OCT * Chronic CSC ≥4 months of duration in one eye, defined as: 1. Subfoveal presence of SRF on OCT 2. Subjective visual loss/symptoms 3. Characteristic appearance of chronic CSC on FAF, fluorescein angiography (FA), and indocyanin angiography (ICGA) and OCT 4. Patient history and examination consistent with chronic CSC Exclusion Criteria: * History of retinal disease other than CSC (e.g. retinal detachment) * Contraindications for FA, ICGA or PDT (only for chronic CSC)

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}